摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo[3,2-c]quinoline | 122456-28-4

中文名称
——
中文别名
——
英文名称
1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo[3,2-c]quinoline
英文别名
4,6-Dimethyl-1-o-tolyl-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline;4,6-dimethyl-1-(2-methylphenyl)-2,3-dihydropyrrolo[3,2-c]quinoline
1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo[3,2-c]quinoline化学式
CAS
122456-28-4
化学式
C20H20N2
mdl
——
分子量
288.392
InChiKey
NKSVVROSSLQQJO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    16.1
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    4-氯-3-(2-氯乙基)-2,8-二甲基喹啉2-甲基苯胺 盐酸盐碳酸氢钠 、 silica gel 、 二氯甲烷乙醇 作用下, 以 正丁醇 为溶剂, 反应 96.0h, 以gave 1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo-[3,2-c]quinoline (1.95 g, 23%), m.p. 126°-128°的产率得到1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo[3,2-c]quinoline
    参考文献:
    名称:
    Dihydropyrrolo quinoline derivatives
    摘要:
    1,4-取代的2,3-二氢吡咯并[3,2-c]喹啉是H.sup.+ K.sup.+ ATPase活性的抑制剂,可用作胃酸分泌的抑制剂。该发明的化合物是1-(2-甲基苯基)-4-氨基-6-甲基-2,3-二氢吡咯并[3,2-c]喹啉。
    公开号:
    US05051508A1
点击查看最新优质反应信息

文献信息

  • Dihydropyrrolo quinoline derivatives
    申请人:SmithKline Beckman Intercredit B.V.
    公开号:US05051508A1
    公开(公告)日:1991-09-24
    1,4-Substituted 2,3-dihydropyrrolo[3,2-c]quinolines which are inhibitors of H.sup.+ K.sup.+ ATPase activity and useful as inhibitors of gastric acid secretion. A compound of the invention is 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline.
    1,4-取代的2,3-二氢吡咯并[3,2-c]喹啉是H.sup.+ K.sup.+ ATPase活性的抑制剂,可用作胃酸分泌的抑制剂。该发明的化合物是1-(2-甲基苯基)-4-氨基-6-甲基-2,3-二氢吡咯并[3,2-c]喹啉。
  • TOPICAL FORMULATIONS
    申请人:BECK Petra Helga
    公开号:US20100093691A1
    公开(公告)日:2010-04-15
    There is provided topical pharmaceutical compositions comprising compounds of formula I wherein R 1 , R 2 , R 3 and X have meanings given in the description. These compositions can be used to treat microbial infections and to kill clinically latent microorganisms.
    提供了一种含有I式化合物的局部制药组合物,其中R1、R2、R3和X的含义在说明中给出。这些组合物可用于治疗微生物感染并杀死临床潜伏微生物。
  • USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS
    申请人:Beck Petra Helga
    公开号:US20120231995A1
    公开(公告)日:2012-09-13
    There is provided the use of compounds of formula I wherein R 1 , R 2 , R 3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.
    提供了使用式子I中的化合物,其中R1、R2、R3和X的含义在说明中给出,用于制备杀死临床潜伏微生物的药物。还提供了使用式子I中的化合物治疗微生物感染的方法,以及某些式子I中的化合物本身。
  • Quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
    申请人:SMITHKLINE BEECHAM INTERCREDIT B.V.
    公开号:EP0307078A1
    公开(公告)日:1989-03-15
    in which R¹ to R⁴ are the same or different and are inter alia, each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, R¹⁰ is inter alia hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂)nOH in which n is 0 to 4 or amino; and A is -(CH₂)₂-, (CH₂)₃- ­or -CH=CH-; processes for their preparation, pharmaceutical compositions containing them and their use in therapy as inhibitors of gastric acid secretion.
    C₁₋₄烷硫基、C₁₋₄烷酰基、氨基、R⁵至 R⁹相同或不同且各自为氢、C₁₋₆alkyl、C₁₋₆alkoxy、C₁₋₆烷硫基、卤素、氰基、氨基、羟基、氨基甲酰基、羧基、C₁₋₆烷酰基、三氟甲基或硝基,R¹⁰除其他外为氢、C₁₋₆烷基、C₁₋₆烷氧基、卤素、羟基、-CH₂OH、C₁₋₆烷硫基、NH(CH₂)nOH(其中 n 为 0 至 4)或氨基;和 A 是-(CH₂)₂-、(CH₂)₃- 或-CH=CH-;它们的制备工艺、含有它们的药物组合物以及它们作为胃酸分泌抑制剂在治疗中的用途。
  • VASODILATOR FOR USE TO TREAT MICROBIAL INFECTIONS
    申请人:Helperby Therapeutics Limited
    公开号:EP3228314A1
    公开(公告)日:2017-10-11
    The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an α-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.
    本发明涉及一种或多种选自下列生物活性剂类别的化合物的用途:一种α-肾上腺素能拮抗剂、一种驱虫药、一种抗真菌药、一种抗疟药、一种抗肿瘤药、一种抗精神病药、一种抗氧化剂、一种血管扩张剂和/或一种维生素,或其药学上可接受的衍生物,用于治疗微生物感染,特别是用于杀死与这种感染有关的繁殖的、非繁殖的和/或临床上潜伏的微生物。
查看更多